Incyte (INCY)
(Delayed Data from NSDQ)
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: PTC, Covanta Holding, Etsy, Incyte and AMAG Pharmaceuticals
5 Toxic Stocks to Get Rid Of or Play Short to Make Gains
by Zacks Equity Research
Exaggerated price of toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.
Incyte (INCY) Up 26.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights: Covanta Holding, Etsy, PTC, Incyte and Vertex Pharmaceuticals
5 Toxic Stocks to Dump or Play Short to Make Gains
by Zacks Equity Research
Unreasonably high price of toxic stocks is only short-lived as the intrinsic value of these stocks is lower than the current bloated price.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
A Trip to 8-Year Bull Run: What's Up, What's Down
by Sweta Killa
While all the three major indices more than tripled scaling multiple highs in recent months, Nasdaq has won the maximum in the eight-year bull run.
5 Toxic Stocks to Abandon or Play Short Right Now
by Zacks Equity Research
In general, toxic stocks are burdened with huge debt loads and vulnerable to external shocks.
What's Driving Lilly's (LLY) Shares after 2016 Decline?
by Zacks Equity Research
After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
by Zacks Equity Research
Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.
Lilly's Olumiant Gets Marketing Authorization in Europe
by Zacks Equity Research
Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Prothena, Acorda Therapeutics and Axovant Sciences
What's in Store for Avis Budget (CAR) this Earnings Season?
by Zacks Equity Research
Avis Budget Group Inc. (CAR) is scheduled to report fourth-quarter 2016 results after market closes on Feb 15.
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
by Zacks Equity Research
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
VASCO (VDSI) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
VASCO Data Security International Inc. (VDSI) is set to report fourth-quarter 2016 results after markets close on Feb 14.
Should You Sell Incyte (INCY) Before Earnings?
by Zacks Equity Research
Incyte (INCY) looks like an exciting pick for investors as it is poised to beat at earnings season.
Alexion (ALXN) Q4 Earnings: Can the Stock Pull a Surprise?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.
5 Toxic Stocks to Dump or Play Short for Gains
by Zacks Equity Research
Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
Can Prothena (PRTA) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is scheduled to report fourth-quarter 2016 results on Feb 14 after the market closes.
Gilead Sciences (GILD) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Gilead Sciences Inc. (GILD ) is scheduled to report fourth-quarter 2016 results on Feb 7, after the market closes.
GW Pharmaceuticals (GWPH) Q1 Earnings: What's in Store?
by Zacks Equity Research
GW Pharmaceuticals plc (GWPH) is scheduled to report first-quarter fiscal 2017 results on Feb 7, before the opening bell.
Mallinckrodt (MNK) Earnings This Quarter: Stock to Disappoint?
by Zacks Equity Research
Mallinckrodt plc (MNK) is set to report results for the quarter ended Dec. 30, 2016 on Feb 7.